Y
Yao Lei
Researcher at Yangzhou University
Publications - 6
Citations - 93
Yao Lei is an academic researcher from Yangzhou University. The author has contributed to research in topics: Epitope & Antigen. The author has an hindex of 3, co-authored 5 publications receiving 51 citations.
Papers
More filters
Journal ArticleDOI
Application of built-in adjuvants for epitope-based vaccines
TL;DR: The current and prospective applications of these built-in adjuvants (i.e., biological carriers) are discussed to provide some references for the future design of epitope-based vaccines.
Journal ArticleDOI
Artificially designed hepatitis B virus core particles composed of multiple epitopes of type A and O foot‐and‐mouth disease virus as a bivalent vaccine candidate
Yao Lei,Shao Junjun,Fu-Rong Zhao,Li Yangfan,Chenglin Lei,Feifei Ma,Huiyun Chang,Yong-Guang Zhang +7 more
TL;DR: It is demonstrated that the VLPs constructed in the current study induced both humoral and cellular immune responses and may represent potential bivalent VLP vaccines targeting both FMDV type A and O strains.
Journal ArticleDOI
Enhanced efficacy of a multi-epitope vaccine for type A and O foot‑and-mouth disease virus by fusing multiple epitopes with Mycobacterium tuberculosis heparin-binding hemagglutinin (HBHA), a novel TLR4 agonist
TL;DR: The multi-epitope immunogen, HAO, of foot-and-mouth disease virus serotypes A and O was fused with the recombinant protein, heparin-binding hemagglutinin (HBHA), a novel TLR4 agonist, to obtain a new recombinant fusion protein, termed HAO-HBHA.
Journal ArticleDOI
A Listeria ivanovii balanced‐lethal system may be a promising antigen carrier for vaccine construction
Yao Lei,Yu-Zhen Zhou,Yunwen Zhang,Si-Jing Liu,Sicheng Tian,Qian Ou,Ting Liu,Huan Huang,Tian Tang,Chuan Wang +9 more
TL;DR: Sequential immunization with different recombinant Listeria strains will significantly enhance the immunotherapeutic effect and LIΔdd:dal combined with LMΔ dd:dal, or with other balanced-lethal systems will be more promising alternative for vaccine development.
Patent
Foot-and-mouth disease virus bivalent multi-epitope recombinant virus-like particle and application thereof
TL;DR: In this paper, a foot-and-mouth disease virus bivalent multi-epitope recombinant virus-like particle (VLP) was constructed by reasonably connecting main antigen epitopes of FMDV strains A and O in series respectively and inserting the main antigene epitopes into two THBcAg molecules of a THbcAg dimer respectively.